Printer Friendly

BIOGEN, INC. APPOINTS DR. IAN HIRST AS DIRECTOR OF MANUFACTURING

 BIOGEN, INC. APPOINTS DR. IAN HIRST AS DIRECTOR OF MANUFACTURING
 CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) today announced the appointment of Dr. Ian Hirst to the position of director of manufacturing. Hirst will be responsible for all manufacturing activities at Biogen. He reports to James C. Mullen, Biogen's vice president-operations.
 Hirst joins Biogen after early manufacturing experience with Imperial Chemical Industries in England. For the last 10 years, Hirst was with SmithKline Beecham, Pharmaceuticals Division, where he held a series of increasingly responsible positions in manufacturing, including that of director of process development.
 Hirst is a graduate of Huddersfield College of Technology in England and received his Ph.D. in organic chemistry from Sheffield University in England. He spent a year at Heidelberg University in Germany as a post- doctoral research fellow with Professor G. Wittig. He is a member of the American Chemical Society, a member of the Royal Society of Chemistry and a chartered chemist.
 Biogen, Inc., headquartered in Cambridge, is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human health care through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of six products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS and certain cancers.
 -0- 8/26/92
 /CONTACT: Kathryn Bloom, director of communications, 617-252-9851; Amy Seltzer, director of investor relations, 617-252-9897; or Michelle Payette, communications assistant, 617-252-9837, of Biogen/
 (BGEN) CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: PER


CH-CN -- NE005 -- 3442 08/26/92 11:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 26, 1992
Words:273
Previous Article:FPL NEWS MEDIA SUMMARY: HURRICANE ANDREW RESTORATION REPORT
Next Article:FIRST VIRGINIA ANNOUNCES ANOTHER DIVIDEND INCREASE
Topics:


Related Articles
BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT
BIOGEN APPOINTS MULLEN TO VICE PRESIDENT-OPERATIONS
BIOGEN, INC. APPOINTS AMY D. SELTZER AS DIRECTOR -- INVESTOR RELATIONS
BIOGEN ANNOUNCES APPOINTMENT OF MICHAEL J. ASTRUE AS VICE PRESIDENT AND GENERAL COUNSEL
BIOGEN ANNOUNCES MANAGEMENT REALIGNMENT AS NEXT STEP IN TRANSITION FROM R&D ORGANIZATION TO OPERATING COMPANY
CREATIVE BIOMOLECULES AND BIOGEN SIGN MANUFACTURING AGREEMENT
BIOGEN APPOINTS DAVID DLESK AS SENIOR DIRECTOR OF MANUFACTURING AND ENGINEERING
Biogen Appoints James Green, Ph.D., As Director, Preclinical Development
Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader.
BioWa Announces the Licensing of its Potelligent(TM) Technology to Biogen Idec.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters